EUVIMEDEUVIMED entdecken
Crossref

Chitosan Nanoparticle Based Mucoadhesive and Mucopenetrating Vaginal Drug Delivery Systems

Devyani P. Chavan, Sapana P. Ahirrao

International Journal of Drug Delivery Technology · 01.07.2026 · 16 (60s)

DOI: 10.25258/ijddt.16.60s.60 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 01.07.2026. Verfasst von Devyani P. Chavan und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The female reproductive tract (FRT) presents a restrictive landscape for conventional therapies, which typically suffer a 90% dose loss due to the "Leakage and Clearance" paradox. This review synthesizes current advancements in chitosannanoparticle (CS-NP) systems, which leverage a pH-responsive apparent pKa of approximately 6.5 to ensure stability in the acidic vaginal lumen (pH 3.8-4.5). Materials and Methods To optimize therapeutic outcomes, researchers have engineered adaptive surfaces that navigate the 340 ± 70 nm cervicovaginal mucus (CVM) mesh. Technical comparisons demonstrate that thiolated "thiomers" (TCS) utilize covalent disulfide exchange (Polymer-SH + Mucin-SH ⇌ Polymer-S-S-Mucin + 2H⁺ + 2e⁻) to achieve a 140-fold increase in mucosal retention. Conversely, mucus-penetrating particles (MPPs) functionalized with dense polyethylene glycol (PEG) shield surface charges to facilitate deep epithelial access.

Results

State-of-the-art (SOTA) applications include Tenofovir-loaded multiunit carriers for HIV prevention, which achieve entrapment efficiencies of 68.9%, and hybrid lipid-chitosan nanoparticles that enhance steroid flux (J) for hormone replacement. The narrative identifies the integration of Artificial Intelligence (AI) in rational design—achieving test-set predictive accuracies of R² = 0.9943—and the emergence of Microbiome-Active Drug Delivery Systems (MADDS) that utilize microbial metabolites as release triggers.

Conclusion

Finally, the review addresses the 2025 regulatory updates from the FDA and EMA, emphasizing the need for standardized characterization to overcome translational bottlenecks. This comprehensive analysis positions CS-NPs as a high-precision platform for treating infectious, oncogenic, and endocrine disorders of the FRT.

Zitieren

APA

Chavan, D. P., & Ahirrao, S. P. (2026). Chitosan Nanoparticle Based Mucoadhesive and Mucopenetrating Vaginal Drug Delivery Systems. International Journal of Drug Delivery Technology, 16(60s). https://doi.org/10.25258/ijddt.16.60s.60

Vancouver

Chavan DP, Ahirrao SP. Chitosan Nanoparticle Based Mucoadhesive and Mucopenetrating Vaginal Drug Delivery Systems. International Journal of Drug Delivery Technology. 2026;16(60s). doi:10.25258/ijddt.16.60s.60

BibTeX
@article{Chavan2026,
  author = {Chavan, Devyani P. and Ahirrao, Sapana P.},
  title = {Chitosan Nanoparticle Based Mucoadhesive and Mucopenetrating Vaginal Drug Delivery Systems},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {60s},
  doi = {10.25258/ijddt.16.60s.60}
}
Kostenlos starten →